2024
Epidemiology and risk factors for hyperkalaemia in heart failure
Grobbee D, Filippatos G, Desai N, Coats A, Pinto F, Rosano G, Cleland J, Kammerer J, de Arellano A. Epidemiology and risk factors for hyperkalaemia in heart failure. ESC Heart Failure 2024, 11: 1821-1840. PMID: 38439165, PMCID: PMC11287317, DOI: 10.1002/ehf2.14661.Peer-Reviewed Original ResearchHeart failureObservational studyRisk factorsRenin-angiotensin-aldosterone system inhibitorsSevere renal impairmentElevated serum potassiumImpaired renal functionRisk of hyperkalaemiaIncreased risk of mortalityAdverse cardiovascular eventsClinical epidemiological dataFollow-up lengthChronic kidney diseaseRisk of mortalityIdentified risk factorsMild hyperkalaemiaPotassium bindersRenal impairmentConcomitant medicationsHF therapyDiagnosed HFRenal functionSerum potassiumClinical careClinical outcomes
2023
Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction
Fuery M, Leifer E, Samsky M, Sen S, O'Connor C, Fiuzat M, Ezekowitz J, Piña I, Whellan D, Mark D, Felker G, Desai N, Januzzi J, Ahmad T. Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 12: 479-487. PMID: 38127049, DOI: 10.1016/j.jchf.2023.11.007.Peer-Reviewed Original ResearchNT-proBNP measurementsPrimary trial endpointChronic heart failureNT-proBNP levelsReduced ejection fractionTrial endpointsHeart failureEjection fractionN-terminal pro-B-type natriuretic peptide (NT-proBNP) measurementBaseline NT-proBNP levelsChronic heart failure patientsNT-proBNP monitoringSecondary trial endpointsHeart failure hospitalizationNatriuretic peptide measurementHeart failure patientsCardiovascular deathFailure hospitalizationNT-proBNPFailure patientsPrognostic impactClinical outcomesPrognostic valueOutpatient sitesClinical studiesImpact Of Digital Health Interventions In The Quality Of Life Of Patients With Heart Failure: A Randomized Trial
Castro A, Martin M, Desai N, Ahmad T, Yamamoto Y, Melchinger H, Lee K, Gerber B, Nguyen A, Weinstein J, Subair L, Lee V, Williams A, Shaw M, Arora T, Wilson F. Impact Of Digital Health Interventions In The Quality Of Life Of Patients With Heart Failure: A Randomized Trial. Journal Of Cardiac Failure 2023, 29: 662. DOI: 10.1016/j.cardfail.2022.10.284.Peer-Reviewed Original ResearchQuality of lifeUsual careClinical summary scoreTotal symptom scoreHeart failureSymptom scoresSummary scoresKansas City Cardiomyopathy Questionnaire overall scoreYale New Haven Health SystemDigital health toolsHealth toolsReduced ejection fractionResults One hundred fiftyUsual care groupMethods One hundred eightyNon-Hispanic blacksDigital health interventionsHF clinicSecondary outcomesEjection fractionEmergency visitsMedian agePrimary outcomeClinical outcomesRandomization groupClinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States
Desai N, Sutton M, Xie J, Fine J, Gao W, Owens A, Naidu S. Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal Of Cardiology 2023, 192: 16-23. PMID: 36709525, DOI: 10.1016/j.amjcard.2022.12.030.Peer-Reviewed Original ResearchConceptsObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyIndex dateCardiovascular eventsIncidence rateSymptomatic obstructive hypertrophic cardiomyopathyAtrial fibrillation/flutterCommon cardiovascular eventMonths continuous eligibilityHealthcare resource utilizationMedicare Supplemental databasesIBM MarketScan CommercialEligible patientsDiagnosis dateMarketScan CommercialClinical outcomesContinuous eligibilityTreatment optionsCumulative riskPatientsResource utilizationPharmacotherapyCardiomyopathyDisease
2020
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes